SCHEMBL4040549

SCHEMBL4040549

COc1ccc(-n2nc(Nc3cccc(OCc4ccccc4)c3)nc2N)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 6/20 0.55
ALDH1A1 P00352 3/20 0.48
DYRK1B Q9Y463 2/20 0.48
DYRK1A Q13627 1/20 0.48
MAOB P27338 1/20 0.46
IMPDH2 P12268 1/20 0.46
SYK P43405 1/20 0.45
AURKA O14965 1/20 0.45
JAK2 O60674 1/20 0.45
KIT P10721 1/20 0.45
IRAK4 Q9NWZ3 1/20 0.45
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
RECQL P46063 1/20 0.44
BLM P54132 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
BCHE P06276 1/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4037275 0.93 FLT3 (0.56) FLT3ALDH1A1DYRK1BDYRK1AMAOB
SCHEMBL4041081 0.92 FLT3 (0.56) FLT3ALDH1A1MAOBIMPDH2SYK
SCHEMBL4039213 0.84 FLT3 (0.64) FLT3ALDH1A1IMPDH2AURKAJAK2
SCHEMBL4044251 0.82 FLT3 (0.60) FLT3ALDH1A1IMPDH2SYKAURKA
SCHEMBL4041560 0.82 FLT3 (0.60) FLT3ALDH1A1SYKAURKAJAK2
SCHEMBL4038398 0.80 FLT3 (0.62) FLT3ALDH1A1IMPDH2AURKAJAK2
SCHEMBL4038418 0.79 FLT3 (0.65) FLT3ALDH1A1IMPDH2AURKAJAK2
SCHEMBL4039047 0.79 SYK (0.58) FLT3ALDH1A1MAOBSYKAURKA
SCHEMBL12780091 0.78 FLT3 (0.47) FLT3ALDH1A1MAOBSYKAURKA
SCHEMBL4038920 0.77 ALDH1A1 (0.59) FLT3ALDH1A1MAPTMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 FLT3 220/4885ALDH1A1 3235/4885DYRK1B 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.